BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31648954)

  • 1. Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience.
    Patel DA; Johanns TM; Trinkaus K; Bartlett NL; Wagner-Johnston N; Cashen AF
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):806-811. PubMed ID: 31648954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
    Sang W; Zhou H; Qin Y; Shen Z; Yan D; Sun C; Song X; Ma Y; Tu D; Bian Z; Nie S; Jin Y; Xu L; Li Z; Xu K
    Int J Hematol; 2021 Aug; 114(2):189-198. PubMed ID: 33893987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.
    Lim RMH; Chan NPX; Khoo LP; Cheng CL; Tan L; Poon EYL; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
    Sci Rep; 2020 Mar; 10(1):4373. PubMed ID: 32152442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
    Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
    Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma.
    Witte HM; Riecke A; Mayer T; Bartscht T; Rades D; Lehnert H; Merz H; Fetscher S; Biersack H; Gebauer N
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):129-136. PubMed ID: 30327940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current therapeutic strategies for diffuse large B‑cell lymphoma].
    Pfreundschuh M
    Internist (Berl); 2016 Mar; 57(3):214-21. PubMed ID: 26847364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.